Skip to main content
OpenTrials
Completed

NCT Number: NCT03754556

Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs

Study to analyze electronic medical records of women using an intrauterine device (IUD). The study was required by the FDA for the marketed IUD Mirena (US Post-marketing requirement; short name of study: APEX IUD).

The study analyzed the risks that the IUD was expelled or perforated the womb for the following group comparisons:

* Women who were breastfeeding at the time of IUD insertion and within 52 weeks postpartum versus women who were not breastfeeding at the time of IUD insertion and within 52 weeks postpartum. * Women who had a first observed IUD insertion within different time periods after childbirth (i.e., ≤ 6 weeks, > 6 weeks and ≤ 14 weeks, > 14 weeks and ≤ 52 weeks) versus women who had their first observed IUD insertion more than 52 weeks after childbirth, including women without a recorded delivery within the past 52 weeks. An additional analysis involved 5-level postpartum timing (i.e., 0 to 3 days, 4 days to ≤ 6 weeks, > 6 weeks to ≤ 14 weeks, > 14 weeks to ≤ 52 weeks) versus the > 52 week postpartum group.

The study also analyzed the risks that the IUD was expelled or perforated the womb for different types of IUDs. In addition, the study aimed to assess the following interactions:

* The extent to which the type of IUD (IUDs releasing the hormone LNG versus Copper IUDs) modified the risk that an IUD was expelled or perforated the womb in relation to breastfeeding and/ or in relation to the point in time when the IUD was inserted after childbirth. * The extent to which the breastfeeding status modified the risk that an IUD was expelled or perforated the womb in relation to the point in time when the IUD was inserted after childbirth.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intrauterine Devices Behavior Breast Feeding Feeding Behavior Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Rupture Urogenital Diseases Uterine Diseases Uterine Perforation Uterine Rupture Wounds and Injuries

Age range

Up to 50 year

Sex eligibility

Female

Study type

Observational

Primary location

Kaiser Permanente Northern California, Oakland, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with evidence in the database of insertion of an IUD (e.g. levonorgestrel-releasing, copper) during the study time window for each site
  • Enrolled in the database with electronic medical records available for review for at least 12 months before the IUD insertion

Exclusion criteria

  • Women with more than 50 years of age at the time of the IUD-insertion

Treatment and study plan

Intrauterine device

Device

Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard

Other names: Levonorgestrel, Copper IUD

Primary outcomes

  1. Crude Incidence Rate of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions

    Time frame: Up to 11 years

    Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years)

  2. Cumulative Incidence of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions

  3. Adjusted Hazard Ratio (HR) for Breastfeeding Status and Uterine Perforation-first Observed IUD Insertions

    Time frame: Up to 11 years

    Propensity score-adjusted hazard ratio to evaluate whether the risk of uterine perforation among women who were breastfeeding at the time of first observed IUD insertion differs from the risk of uterine perforation among women who were not breastfeeding at the time of first observed IUD insertion

  4. Crude Incidence Rate of Uterine Perforation Categorized by Postpartum Timing-first Observed IUD Insertions

    Time frame: Up to 11 years

    Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years)

  5. Cumulative Incidence of Uterine Perforation Categorized by Postpartum Timing-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions

  6. Adjusted Hazard Ratio (HR) for Postpartum Timing and Uterine Perforation-first Observed IUD Insertions

    Time frame: Up to 11 years

    Adjusted for propensity scores and breastfeeding status, to evaluate whether the risk of uterine perforation among women who had a first observed IUD insertion within different time periods postpartum differs from the risk of uterine perforation among women who had their first observed IUD insertion more than 52 weeks postpartum, including women without a recorded delivery within the past 52 weeks. Reference group: IUD insertion > 52 weeks postpartum

  7. Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 14-week Cut Point and Uterine Perforation-first Observed IUD Insertions

    Time frame: Up to 11 years

    Adjusted for propensity scores and breastfeeding status, to estimate the risk of uterine perforation among women who had a first observed IUD insertion early in the postpartum period (i.e., up to 14 weeks postpartum) versus those who had a first observed IUD insertion late in the postpartum period (i.e., more than 14 weeks postpartum, including women without recorded delivery within the past 52 weeks). Reference group: IUD insertion >14 weeks postpartum or with no recorded delivery

  8. Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 36-week Cut Point and Uterine Perforation-first Observed IUD Insertions

    Time frame: Up to 11 years

    Adjusted for propensity scores and breastfeeding status, to estimate the risk of uterine perforation among women who had a first observed IUD insertion ≤ 36 weeks postpartum versus women who had a first observed IUD insertion > 36 weeks postpartum, including women without recorded delivery within the past 52 weeks. Reference group: IUD insertion >36 weeks postpartum or with no recorded delivery

  9. Adjusted Incidence Rate Ratio (IRR) for Uterine Perforation-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Adjusted for propensity score, overall and stratified by breastfeeding status at the time of IUD insertion for ≤ 36 weeks postpartum at IUD insertion versus > 36 weeks postpartum or with no recorded delivery, at 1 year and 5 years of follow-up. Reference group: > 36 weeks or no delivery

  10. Adjusted Incidence Rate Difference (IRD) for Uterine Perforation-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Propensity score-adjusted incidence rate differences (per 1,000 person-years) for uterine perforation for women ≤ 36 weeks postpartum at IUD insertion compared with those who were > 36 weeks postpartum or with no recorded delivery, 1 year of follow-up and 5 years of follow-up, overall and stratified by breastfeeding status. Reference group: > 36 weeks or no delivery

  11. Crude Incidence Rate of Uterine Perforation Stratified by IUD Type-first Observed IUD Insertions

    Time frame: Up to 11 years

    Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years)

  12. Cumulative Incidence of Uterine Perforation Stratified by IUD Type-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions

  13. Adjusted Hazard Ratio (HR) for IUD Type and Uterine Perforation-first Observed IUD Insertions

    Time frame: Up to 11 years

    Propensity score-adjusted hazard ratio to evaluate whether the risk of uterine perforation among women with LNG-releasing IUD at the time of first observed IUD insertion differs from the risk of uterine perforation among women with copper IUD at the time of first observed IUD insertion

  14. Crude Incidence Rate of Uterine Perforation Stratified by Menorrhagia Status-first Observed IUD Insertions

    Time frame: Up to 11 years

    Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years)

  15. Cumulative Incidence of Uterine Perforation Stratified by Menorrhagia Status-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions

  16. Adjusted Hazard Ratio (HR) for Menorrhagia Status and Uterine Perforation-first Observed IUD Insertions

    Time frame: Up to 11 years

    Propensity score-adjusted hazard ratio to evaluate whether the risk of uterine perforation among women using an IUD who have at least one diagnosis code indicating menorrhagia in the 12 months before IUD insertion differs from the risk of uterine perforation among women who do not have this indication

  17. Effect Modification of Breastfeeding Status on Postpartum Timing for Uterine Perforation

    Time frame: Up to 11 years

    Propensity score-adjusted hazard ratios to evaluate the extent to which breastfeeding status (yes vs. no) modified the association of uterine perforation for women with IUD insertion at different time periods postpartum (i.e., IUD insertion ≤ 14 weeks versus IUD insertion > 14 weeks postpartum) among women with a recorded delivery within the past 52 weeks at the time of the first observed IUD insertion

  18. Effect Modification of IUD Type on Breastfeeding Status for Uterine Perforation

    Time frame: Up to 11 years

    Propensity score-adjusted hazard ratios to evaluate the extent to which type of IUD (LNG-IUD vs. copper IUD) modified the association between uterine perforation and breastfeeding among women who were and were not breastfeeding at the time of first observed IUD insertion

  19. Effect Modification of IUD Type on Postpartum Timing for Uterine Perforation

    Time frame: Up to 11 years

    Adjusted for propensity score and breastfeeding status, to evaluate the extent to which type of IUD (LNG-IUD vs. copper IUD) modified the association between uterine perforation and postpartum timing of IUD insertion for women with IUD insertion at different time periods postpartum (i.e., ≤ 6 weeks, > 6 and ≤ 14 weeks, > 14 and ≤ 52 weeks) versus IUD insertion more than 52 weeks postpartum, including no recorded delivery within the past 52 weeks, at the time of the first observed IUD insertion. Reference group: LNG-IUD or Copper IUD, > 52 weeks or no delivery

Secondary outcomes

  1. Crude Incidence Rate of IUD Expulsion Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions

    Time frame: Up to 11 years

    Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years)

  2. Cumulative Incidence of IUD Expulsion Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions

  3. Adjusted Hazard Ratio (HR) for Breastfeeding Status and IUD Expulsion-first Observed IUD Insertions

    Time frame: Up to 11 years

    Propensity score-adjusted to evaluate whether the risk of IUD expulsion among women who were breastfeeding at the time of first observed IUD insertion differs from the risk of IUD expulsion among women who were not breastfeeding at the time of first observed IUD insertion

  4. Crude Incidence Rate of IUD Expulsion Categorized by Postpartum Timing-first Observed IUD Insertions

    Time frame: Up to 11 years

    Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years)

  5. Cumulative Incidence of IUD Expulsion Categorized by Postpartum Timing-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions

  6. Adjusted Hazard Ratio (HR) for Postpartum Timing and IUD Expulsion-first Observed IUD Insertions

    Time frame: Up to 11 years

    Adjusted for propensity score and breastfeeding status, to evaluate whether the risk of IUD expulsion before and after 49 days of insertion among women who had a first observed IUD insertion within different time periods postpartum differs from the risk of IUD expulsion among women who had their first observed IUD insertion more than 52 weeks postpartum, including women without a recorded delivery within the past 52 weeks Reference group: IUD insertion > 52 weeks postpartum

  7. Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 14-week Cut Point and IUD Expulsion-first Observed IUD Insertions

    Time frame: Up to 11 years

    Adjusted for propensity scores, to estimate the risk of IUD expulsion among women who had a first observed IUD insertion early in the postpartum period (i.e., up to 14 weeks postpartum) versus those who had a first observed IUD insertion late in the postpartum period (i.e., more than 14 weeks postpartum, including women without recorded delivery within the past 52 weeks). Reference group: IUD insertion >14 weeks postpartum or with no recorded delivery

  8. Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 36-week Cut Point and IUD Expulsion-first Observed IUD Insertions

    Time frame: Up to 11 years

    Adjusted for propensity scores, to estimate the risk of IUD expulsion among women who had a first observed IUD insertion ≤ 36 weeks postpartum versus women who had a first observed IUD insertion > 36 weeks postpartum, including women without recorded delivery within the past 52 weeks. Reference group: IUD insertion >36 weeks postpartum or with no recorded delivery

  9. Adjusted Incidence Rate Ratio (IRR) for IUD Expulsion-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Overall and stratified by breastfeeding status at the time of IUD insertion for IUD expulsion for ≤ 36 weeks postpartum at IUD insertion versus > 36 weeks postpartum or with no recorded delivery, at 1 year and 5 years of follow-up Reference group: > 36 weeks or no delivery

  10. Adjusted Incidence Rate Difference (IRD) for IUD Expulsion-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Adjusted incidence rate differences (per 1,000 person-years) for IUD expulsion for women ≤ 36 weeks postpartum at IUD insertion compared with those who were > 36 weeks postpartum or with no recorded delivery, 1 year of follow-up and 5 years of follow-up, overall and stratified by breastfeeding status Reference group: > 36 weeks or no delivery

  11. Crude Incidence Rate of IUD Expulsion Stratified by IUD Type-first Observed IUD Insertions

    Time frame: Up to 11 years

    Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years)

  12. Cumulative Incidence of IUD Expulsion Stratified by IUD Type-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions

  13. Adjusted Hazard Ratio (HR) for IUD Type and IUD Expulsion-first Observed IUD Insertions

    Time frame: Up to 11 years

    Propensity score adjusted to evaluate whether the risk of IUD expulsion among women with LNG-releasing IUD at the time of first observed IUD insertion differs from the risk of IUD expulsion among women with copper IUD at the time of first observed IUD insertion

  14. Crude Incidence Rate of IUD Expulsion Stratified by Menorrhagia Status-first Observed IUD Insertions

    Time frame: Up to 11 years

    Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years)

  15. Cumulative Incidence of IUD Expulsion Stratified by Menorrhagia Status-first Observed IUD Insertions

    Time frame: At 1 year and 5 years of follow-up

    Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions

  16. Adjusted Hazard Ratio (HR) for Menorrhagia Status and IUD Expulsion-first Observed IUD Insertions

    Time frame: Up to 11 years

    Propensity score adjusted to evaluate whether the risk of IUD expulsion among women using an IUD who have at least one diagnosis code indicating menorrhagia in the 12 months before IUD insertion differs from the risk of IUD expulsion among women who do not have this indication

  17. Effect Modification of IUD Type on Breastfeeding Status for IUD Expulsion

    Time frame: Up to 11 years

    Propensity score-adjusted hazard ratios to evaluate the extent to which type of IUD (LNG-IUD vs. copper IUD) modified the association between IUD expulsion and breastfeeding among women who were and were not breastfeeding at the time of first observed IUD insertion

  18. Effect Modification of IUD Type on Postpartum Timing for IUD Expulsion

    Time frame: Up to 11 years

    Adjusted for propensity score and breastfeeding status, to evaluate the extent to which type of IUD (LNG-IUD vs. copper IUD) modified the association between IUD expulsion and postpartum timing of IUD insertion for women with IUD insertion at different time periods postpartum (i.e., ≤ 6 weeks, > 6 and ≤ 14 weeks, > 14 and ≤ 52 weeks) versus IUD insertion more than 52 weeks postpartum, including no recorded delivery within the past 52 weeks, at the time of the first observed IUD insertion. Reference group: LNG-IUD or Copper IUD, > 52 weeks or no delivery

  19. Number of Indicators of a Potentially Difficult Insertion, Overall, by Breastfeeding Status, and by Postpartum Timing of IUD Insertion-first Observed IUD Insertions

    Time frame: Up to 11 years

    To describe the prevalence of indicators of a difficult IUD insertion (e.g., need for cervical dilation, ultrasound guidance, paracervical block, clinician not indicating difficulty, use of misoprostol among all users)

  20. Number of Indicators of a Potentially Difficult Insertion, Overall, by IUD Type and by Menorrhagia Status-first Observed IUD Insertions

    Time frame: Up to 11 years

    To describe the prevalence of indicators of a difficult IUD insertion (e.g., need for cervical dilation, ultrasound guidance, paracervical block, clinician not indicating difficulty, use of misoprostol among all users)

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Study on the Association of Uterine Perforation and Intrauterine Device (IUD) Expulsion With Breastfeeding Status at the Time of IUD Insertion and Postpartum Timing of IUD Insertion in Electronic Medical Record Databases - A Postmarketing Requirement for Mirena

Acronym: APEX IUD

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 27, 2018
Registry last updated
Dec 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.